The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines

• Published in: Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology Vol. 20; no. 1; pp. 37 - 50
• Main Authors: Woo, Young Sup, Bahk, Won-Myong, Seo, Jeong Seok, Park, Young-Min, Kim, Won, Jeong, Jong-Hyun, Shim, Se-Hoon, Lee, Jung Goo, Jang, Seung-Ho, Yang, Chan-Mo, Wang, Sheng-Min, Jung, Myung Hun, Sung, Hyung Mo, Choo, Il Han, Yoon, Bo-Hyun, Lee, Sang-Yeol, Jon, Duk-In, Min, Kyung Joon
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean College of Neuropsychopharmacology 28.02.2022; 대한정신약물학회
• Subjects: Review; 정신과학; Pharmacotherapy; Guideline; Consensus; Depressive disorder; KMAP-DD 2021
• ISSN: 1738-1088; 2093-4327
• DOI: 10.9758/cpn.2022.20.1.37

The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) first was published in 2002, and has been revised four times, in 2006, 2012, 2017, and 2021. In this review, we compared recommendations from the recently revised KMAP-DD 2021 to four global clinical practice guidelines (CPGs) for depression published after 2010. The recommendations from the KMAP-DD 2021 were similar to those from other CPGs, although there were some differences. The KMAP-DD 2021 reflected social culture and the healthcare system in Korea and recent evidence about pharmacotherapy for depression, as did other recently published evidence-based guidelines. Despite some intrinsic limitations as an expert consensus-based guideline, the KMAP-DD 2021 can be helpful for Korean psychiatrists making decisions in clinical settings by complementing previously published evidence-based guidelines, especially for some clinical situations lacking evidence from rigorously designed clinical trials.